Fresh headlines from around the world. Gaming, politics, technology and everything in between.
Moderna and Merck’s personalized mRNA vaccine for melanoma reduced the risk of cancer recurrence and death by 42% compared with standard treatment in a trial.
Vacina contra câncer da MSD/Moderna reduz em 42% risco de morte Dado Ruvic A vacina contra o câncer desenvolvida pela Moderna e pela MSD reduziu em 42% o risco de morte ou de retorno do melanoma, o tipo mais agressivo de câncer de pele. O resultado vem do estudo de fase 3, a última etapa de testes antes do pedido de aprovação, e foi divulgado pelas empresas
Beyond melanoma, scientists are studying cancer vaccines for glioblastoma, pancreatic cancer and more.
A major breakthrough in fighting skin cancer has been announced, with an Australian-led trial developing a world first vaccine.
Merck and Moderna released detailed results on an experimental vaccine to treat the skin cancer.
El inyectable ayudó a reducir en un 42% el riesgo de recurrencia del cáncer, resultado que parece haber decepcionado a Wall Street
More people are diagnosed with skin cancer each year in the U.S. than all other cancers combined.
Allnira republishes accessible articles under owner-declared permissions, with original authors, publishers and image credits. Automatic cloud imports run hourly; open pages check for updates every 15 seconds. Publication delays depend on each feed.